Temsirolimus in the treatment of advanced renal cell carcinoma

Main Article Content

Bernard J. Escudier (1*)

1 Institut Gustave Roussy, Villejuif, France.
(*) Corresponding Author:
Bernard J. Escudier


Temsirolimus is a novel inhibitor of mammalian target of rapamycin (mTOR), which is a central regulator of the response of tumour cells to growth and survival signals. When heavily pretreated patients with advanced solid tumours received intravenous (IV) temsirolimus over a broad dose range, antitumour activity was observed in various tumour types, including advanced renal cell carcinoma (RCC). A study of singleagent temsirolimus in patients with cytokine-refractory metastatic RCC subsequently demonstrated antitumour activity and encouraging progression- free survival and overall survival. Temsirolimus was generally well tolerated over the 3 dose levels tested (25 mg, 75 mg or 250 mg weekly as a 30-minute IV infusion). The most frequent grade 3 or 4 treatment-related adverse events reported (n=110) were hyperglycemia (17%), hypophosphatemia (13%), anemia (9%), and hypertriglyceridemia (6%). Results from a randomized phase III study that enrolled previously untreated patients with advanced RCC and poor-prognostic features have recently demonstrated a significant increase in overall survival (p=0.0089) for patients who received temsirolimus 25 mg IV, 30-minute infusion once weekly compared with those who received interferon-alpha up to 18 million units subcutaneously thrice weekly. On the basis of improved survival, temsirolimus can be considered a first-line treatment for patients with advanced RCC.

Downloads month by month


Download data is not yet available.

Article Details

How to Cite
Escudier, B. J. (2011). Temsirolimus in the treatment of advanced renal cell carcinoma. Oncology Reviews, 1(2), 73-80. Retrieved from http://www.oncologyreviews.org/index.php/or/article/view/oncol.2007.73